Nilsson, Niklas http://orcid.org/0000-0002-2047-8058
Storesund, Ingebjørg http://orcid.org/0000-0002-8479-3428
Tho, Ingunn http://orcid.org/0000-0003-4241-4183
Nezvalova-Henriksen, Katerina http://orcid.org/0000-0002-8085-4932
Funding for this research was provided by:
Helse Sør-Øst RHF (2018096)
University of Oslo
Article History
Received: 25 February 2022
Revised: 29 March 2022
Accepted: 1 April 2022
First Online: 14 April 2022
Declarations
:
: This is an in vitro experimental study involving no human or animal subjects. The study is performed according to ethical standards for laboratory experiments.
: Not applicable.
: Not applicable.
: The authors have no relevant financial or none-financial interests to disclose. The Hospital Pharmacy Enterprise had no impact on the design and results reported in this study. Niklas Nilsson and Dr. Katerina Nezvalova-Henriksen work as clinical pharmacists at Oslo University Hospital, Rikshospitalet, consulting in questions regarding medication of neonatal and paediatric intensive care patients.